Faruqi & Faruqi Investigates LifeMD: Deadline for Investors Approaching
In a significant development affecting investors of LifeMD, Inc. (NASDAQ: LFMD), the national law firm Faruqi & Faruqi, LLP has initiated an investigation into potential claims surrounding the company's financial disclosures. This inquiry comes as the deadline for investors to seek the role of lead plaintiff approaches on October 27, 2025. The firm, which has extensive experience in securities law, encourages affected investors to reach out regarding their legal options.
The investigation stems from claims that LifeMD's executives may have made misleading statements regarding the company's standing in the market and its financial projections. Specifically, the complaint suggests that LifeMD materially overstated its competitive position. Furthermore, it alleges that the company was reckless in adjusting its 2025 revenue guidance without adequately accounting for increasing customer acquisition costs in its RexMD segment. This includes the financial implications of marketing drugs aimed at treating obesity, such as Wegovy and Zepbound.
On August 5, 2025, LifeMD released its second-quarter financial results, revealing a substantial drop in expected revenue, revising its earlier guidance from a range of $268-275 million down to $250-255 million. The immediate aftermath saw LifeMD's stock price suffer a dramatic decline of 44.8% the following day.
Investors who sustained losses exceeding $75,000 in LifeMD between May 7, 2025, and August 5, 2025, are encouraged to contact Josh Wilson, a senior partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310). This legal representation could be crucial for those looking to navigate the complexities of securities law and assert their rights in light of the allegations against LifeMD.
The legal mechanism allows any member of the purported class to apply to serve as lead plaintiff, which typically involves overseeing the litigation on behalf of the class. If you opt not to take on this role, your ability to participate in any potential recovery remains unaffected, ensuring that all investors can still benefit from the outcome of the case.
Faruqi & Faruqi is keen to gather more information regarding LifeMD's conduct. They welcome insights from whistleblowers, former employees, shareholders, and anyone with relevant information that could assist in this investigation. Such contributions could prove instrumental in building a stronger case against the company.
To stay updated on the progress of this investigation, interested parties can visit the official webpage set up by Faruqi & Faruqi for the LifeMD class action at www.faruqilaw.com/LFMD. This information hub will provide updates and details on the developments as the situation evolves. Moreover, Faruqi & Faruqi maintains a robust presence across social media platforms, including LinkedIn, X, and Facebook, where they periodically share updates.
As the deadline approaches for investors to assert their claims against LifeMD, it’s crucial for those who believe they may have suffered losses due to misleading financial guidance to act quickly. Engaging with a knowledgeable securities law firm like Faruqi & Faruqi not only allows affected investors to navigate their options but also plays a vital role in holding corporations accountable for their actions in the financial markets. Investors should not delay in reaching out to seek legal counsel and discuss their rights as this important deadline looms.
Context of the Investigation
The investigation stems from claims that LifeMD's executives may have made misleading statements regarding the company's standing in the market and its financial projections. Specifically, the complaint suggests that LifeMD materially overstated its competitive position. Furthermore, it alleges that the company was reckless in adjusting its 2025 revenue guidance without adequately accounting for increasing customer acquisition costs in its RexMD segment. This includes the financial implications of marketing drugs aimed at treating obesity, such as Wegovy and Zepbound.
On August 5, 2025, LifeMD released its second-quarter financial results, revealing a substantial drop in expected revenue, revising its earlier guidance from a range of $268-275 million down to $250-255 million. The immediate aftermath saw LifeMD's stock price suffer a dramatic decline of 44.8% the following day.
What This Means for Investors
Investors who sustained losses exceeding $75,000 in LifeMD between May 7, 2025, and August 5, 2025, are encouraged to contact Josh Wilson, a senior partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310). This legal representation could be crucial for those looking to navigate the complexities of securities law and assert their rights in light of the allegations against LifeMD.
The legal mechanism allows any member of the purported class to apply to serve as lead plaintiff, which typically involves overseeing the litigation on behalf of the class. If you opt not to take on this role, your ability to participate in any potential recovery remains unaffected, ensuring that all investors can still benefit from the outcome of the case.
Encourage Whistleblowers and Former Employees
Faruqi & Faruqi is keen to gather more information regarding LifeMD's conduct. They welcome insights from whistleblowers, former employees, shareholders, and anyone with relevant information that could assist in this investigation. Such contributions could prove instrumental in building a stronger case against the company.
To stay updated on the progress of this investigation, interested parties can visit the official webpage set up by Faruqi & Faruqi for the LifeMD class action at www.faruqilaw.com/LFMD. This information hub will provide updates and details on the developments as the situation evolves. Moreover, Faruqi & Faruqi maintains a robust presence across social media platforms, including LinkedIn, X, and Facebook, where they periodically share updates.
Conclusion
As the deadline approaches for investors to assert their claims against LifeMD, it’s crucial for those who believe they may have suffered losses due to misleading financial guidance to act quickly. Engaging with a knowledgeable securities law firm like Faruqi & Faruqi not only allows affected investors to navigate their options but also plays a vital role in holding corporations accountable for their actions in the financial markets. Investors should not delay in reaching out to seek legal counsel and discuss their rights as this important deadline looms.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.